Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1/2
Tests a PARP inhibitor with heated chemotherapy during surgery for ovarian cancer
Tests a PARP inhibitor with heated chemotherapy in adults with ovarian or fallopian tube cancer.
Key facts
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Where
- Amsterdam and Utrecht, NetherlandsSee the 2 sites
- Trial code
- Registry title
- Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer: The PROOV study - A Phase I/II clinical trial
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 55 people, planned
- Started
- 7 Apr 2025
- Expected to end
- 1 May 2034
- Type of study
- Interventional
- Record updated
- 2 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 or older with ovarian, fallopian tube or extraovarian cancer who have surgery with heated chemotherapy inside the belly (HIPEC).
- Age
- 18 Years or older
- Sex
- Women only
- Disease stage
- Ovarian cancer, fallopian tube cancer or extraovarian cancer.
Where in Netherlands
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests a PARP inhibitor with heated chemotherapy during surgery for ovarian cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 2 October 2026